ARCHIVES

Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

March 2, 2007

NCI Programs: Coleman To Lead NCI’s New Radiation Oncology Program

February 5, 1999

News Analysis by Keith Baggerly: Duke Trials Went On Despite FDA Statements

January 27, 2012

Includes 8-page Business & Regulatory Report.

April 11, 2003

Applications Due Sept. 1 For Cancer Prevention Fellows

May 10, 1991

Carlson Named NCCN Chief Executive

September 28, 2012